Natera’s Signatera wins Japan PMDA approval as companion diagnostic in muscle-invasive bladder cancer - NTRA News | RalliesNatera’s Signatera wins Japan PMDA approval as companion diagnostic in muscle-invasive bladder cancer
N
NTRA• Japan approval for Signatera in bladder cancer
- Natera won PMDA clearance in Japan for Signatera as a companion diagnostic in muscle-invasive bladder cancer.
- Authorization supports MRD-guided adjuvant use of Roche’s Tecentriq (atezolizumab) in eligible post-surgery patients.
- Commercial launch targeted for 1H 2027, pending final reimbursement and pricing decisions.
